Mercer Global Advisors Inc Acelrx Pharmaceuticals Inc Transaction History

Mercer Global Advisors Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	BUY	$0.18 - $0.29 $2,736 - $4,408	15,200 New	15,200 $4,000
Q4 2021 Feb 04, 2022	SELL	$0.49 - $1.02 $68,710 - $143,030	-140,226 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$0.93 - $1.51 $130,410 - $211,741	140,226 New	140,226 $143,000
Q1 2020 May 18, 2020	SELL	$0.76 - $2.07 $77,361 - $210,709	-101,792 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$1.66 - $2.4 $33,200 - $48,000	-20,000 Reduced 16.42%	101,792 $215,000
Q3 2019 Nov 12, 2019	SELL	$2.1 - $2.87 $31,500 - $43,050	-15,000 Reduced 10.97%	121,792 $267,000
Q2 2019 Aug 14, 2019	BUY	$2.1 - $3.93 $202,650 - $379,245	96,500 Added 239.5%	136,792 $346,000
Q1 2019 Apr 23, 2019	BUY	$2.35 - $3.83 $14,100 - $22,980	6,000 Added 17.5%	40,292 $140,000
Q1 2019 Apr 12, 2019	BUY	$2.35 - $3.83 $80,586 - $131,338	34,292 New	34,292 $79,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

Stay updated on Mercer Global Advisors Inc with notifications on news.